1. INTERESTING ANSWERS
    What percent of MDS cases have another concomitant hematopoietic malignancy?
    How many MDS cases Genoptix sees in a year: 500, 1500, 3000 or 5000?
    What percentage of MPNs are associated with other underlying hematopoietic disorders?
    What percent improvement in detection of cytogenetic abnormalities in plasma cell disorders is observed when enrichment of plasma cells is included prior to FISH analysis?
    CLOSE X
  2. INTERESTING ANSWERS
    What percent of MDS cases have another concomitant hematopoietic malignancy?
    How many MDS cases Genoptix sees in a year: 500, 1500, 3000 or 5000?
    What percentage of MPNs are associated with other underlying hematopoietic disorders?
    What percent improvement in detection of cytogenetic abnormalities in plasma cell disorders is observed when enrichment of plasma cells is included prior to FISH analysis?
    Answer: 8.5% of MDS cases have an underlying malignancy
    < BACK
    CLOSE X
  3. INTERESTING ANSWERS
    What percent of MDS cases have another concomitant hematopoietic malignancy?
    How many MDS cases Genoptix sees in a year: 500, 1500, 3000 or 5000?
    What percentage of MPNs are associated with other underlying hematopoietic disorders?
    What percent improvement in detection of cytogenetic abnormalities in plasma cell disorders is observed when enrichment of plasma cells is included prior to FISH analysis?
    ANSWER: 5000 cases.
    < BACK
    CLOSE X
  4. INTERESTING ANSWERS
    What percent of MDS cases have another concomitant hematopoietic malignancy?
    How many MDS cases Genoptix sees in a year: 500, 1500, 3000 or 5000?
    What percentage of MPNs are associated with other underlying hematopoietic disorders?
    What percent improvement in detection of cytogenetic abnormalities in plasma cell disorders is observed when enrichment of plasma cells is included prior to FISH analysis?
    Answer:
    6.8% of MPN cases are associated with a T- or B-cell lymphoproliferative disorder
    1.9% of MPN cases are associated with a plasma cell neoplasm
    < BACK
    Reference: Data on file. N=102, Select COMPASS data collected from 12/1/09-12/31/09
    CLOSE X
  5. INTERESTING ANSWERS
    What percent of MDS cases have another concomitant hematopoietic malignancy?
    How many MDS cases Genoptix sees in a year: 500, 1500, 3000 or 5000?
    What percentage of MPNs are associated with other underlying hematopoietic disorders?
    What percent improvement in detection of cytogenetic abnormalities in plasma cell disorders is observed when enrichment of plasma cells is included prior to FISH analysis?
    Answer: 53% improvement; in a recent study published by Genoptix on the process of plasma cell enrichment prior to FISH analysis (iFISH) increased detection of cytogenetic abnormalities from 28.1% of the time to 87.5% of the time
    < BACK
    CLOSE X